India, Oct. 6 -- Researchers at the University of Missouri have reported findings suggesting that low-dose Rapamycin, an FDA-approved drug primarily used to prevent organ transplant rejection, may improve brain blood flow in middle-aged adults genetically predisposed to Alzheimer's disease.
The study focused on carriers of the APOE4 gene variant, a major genetic risk factor associated with an increased likelihood of developing Alzheimer's disease. According to the researchers, reduced cerebral blood flow often occurs years before cognitive symptoms appear, making it a potential early indicator of disease risk.
In the pilot single-arm trial, cognitively normal adults aged 45 to 65 received low-dose rapamycin for four weeks. Researchers fou...